CLINICAL_TRIALS
trial_result
· 2023-08-21
Clinical Trial Update: Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis [Phase 1]
Summary
Phase 1 trial of a single dose of spesolimab in generalized pustular psoriasis has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Psoriasis | Phase 1 | Status: COMPLETED | Results posted: 2023-08-21